

## CHAPTER 10

# Sexual Aids for Gay and Bisexual Men and Transgender Women after Prostate Cancer Treatments

*Erik Wibowo and Richard Wassersug*

### CHAPTER SUMMARY

Prostate cancer treatments can affect the sexual experience of individuals regardless of sexual orientation. While the absence of orgasm is a common result of most treatments for prostate cancer, some patients have reported experiencing multiple, more intense, or diffuse orgasm after prostate cancer treatment. Interestingly, many transgender women also claim similar orgasmic changes after sexual reassignment. In this chapter we discuss how some products that are marketed as sex aids or “toys” may facilitate sexual recovery after prostate cancer treatments. These products include external penile prostheses, penile sleeves, and penile support devices. We stress the relevance of having a partner or partners for satisfactory sexual recovery. This includes the importance of involving partners in selecting sexual aids and using the aids in a way that develops an erotic association between the aids and the partner. Statistically, gay men are more likely than heterosexual men to be unpartnered. Being single may be a contributing, but under-investigated, factor in the higher level of distress experienced by gay prostate cancer patients in contrast to their heterosexual counterparts.

### KEY TERMS

multiple orgasms, penile sleeve, penis support device, sex aids, sex toys, sexual partner, strap-on dildo, vacuum erection device, vibrators

## REFERENCES

1. Samplaski MK, Lo KC. Erectile dysfunction in the setting of prostate cancer. In Lipshultz LI, Pastuszak AW, Goldstein AT, et al, eds. *Management of sexual dysfunction in men and women*. New York: Springer; 2016: 73–86.
2. McConkey R. Effect of erectile dysfunction following prostate cancer treatment. *Nursing Standard*. 2015; 30 (12): 38–44.
3. Wassersug RJ. Maintaining intimacy for prostate cancer patients on androgen deprivation therapy. *Current Opinion in Supportive and Palliative Care*. 2016; 10 (1): 55–65.
4. Cheung AS, de Rooy C, Hoermann R, et al. Quality of life decrements in men with prostate cancer undergoing androgen deprivation therapy. *Clinical Endocrinology*. 2016; 86 (3): 388–394.
5. Wassersug R, Wibowo E. Non-pharmacological and non-surgical strategies to promote sexual recovery for men with erectile dysfunction. *Translational Andrology and Urology*. 2017; 6 (Suppl. 5): S776–794.
6. Johnson RD, Murray FT. Androgen dependent penile mechanoreceptors in the rat. *Anatomia, Histologia Embryologia*. 1990; 19 (1): 86.
7. Kow LM, Pfaff DW. Effects of estrogen treatment on the size of receptive field and response threshold of pudendal nerve in the female rat. *Neuroendocrinology*. 1973; 13 (4): 299–313.
8. Wibowo E, Wassersug RJ. The effect of estrogen on the sexual interest of castrated males: Implications to prostate cancer patients on androgen-deprivation therapy. *Critical Reviews in Oncology/Hematology*. 2013; 87 (3): 224–238.
9. Gilbert DC, Duong T, Kynaston HG, et al. Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer. *BJU International*. 2016; 119 (5): 667–675.
10. Fode M, Serefoglu EC, Albersen M, Sonksen J. Sexuality following radical prostatectomy: Is restoration of erectile function enough? *Sexual Medicine Reviews*. 2017; 5 (1): 110–119.
11. Wibowo E, Wassersug RJ. Multiple orgasms in men—what we know so far. *Sexual Medicine Reviews*. 2016; 4 (2): 136–148.
12. Frey A, Sonksen J, Jakobsen H, Fode M. Prevalence and predicting factors for commonly neglected sexual side effects to radical prostatectomies: Results from a cross-sectional questionnaire-based study. *Journal of Sexual Medicine*. 2014; 11 (9): 2318–2326.
13. Warkentin KM, Gray RE, Wassersug RJ. Restoration of satisfying sex for a castrated cancer patient with complete impotence: A case study. *Journal of Sex and Marital Therapy*. 2006; 32 (5): 389–399.
14. Wassersug RJ, Lyons A, Duncan D, et al. Diagnostic and outcome differences

- between heterosexual and nonheterosexual men treated for prostate cancer. *Urology*. 2013; 82 (3): 565–571.
15. Rosenberger JG, Schick V, Herbenick D, et al. Sex toy use by gay and bisexual men in the United States. *Archives of Sexual Behavior*. 2012; 41 (2): 449–458.
  16. Gooren L, Morgentaler A. Prostate cancer incidence in orchidectomised male-to-female transsexual persons treated with oestrogens. *Andrologia*. 2014; 46 (10): 1156–1160.
  17. Wibowo E, Calich HJ, Currie RW, Wassersug RJ. Prolonged androgen deprivation may influence the autoregulation of estrogen receptors in the brain and pelvic floor muscles of male rats. *Behavioural Brain Research*. 2015; 286 (2015): 128–135.
  18. Markland C. Transsexual surgery. *Obstetrics and Gynecology Annual*. 1975; 4: 309–330.
  19. Thurston AV. Carcinoma of the prostate in a transsexual. *British Journal of Urology*. 1994; 73 (2): 217.
  20. van Kesteren P, Meinhardt W, van der Valk P, et al. Effects of estrogens only on the prostates of aging men. *Journal of Urology*. 1996; 156 (4): 1349–1353.
  21. van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. *Clinical Endocrinology*. 1997; 47 (3): 337–342.
  22. van Haarst EP, Newling DW, Gooren LJ, et al. Metastatic prostatic carcinoma in a male-to-female transsexual. *British Journal of Urology*. 1998; 81 (5): 776.
  23. Miksad RA, Bublely G, Church P, et al. Prostate cancer in a transgender woman 41 years after initiation of feminization. *JAMA*. 2006; 296 (19): 2316–2317.
  24. Molokwu CN, Appelbaum JS, Miksad RA. Detection of prostate cancer following gender reassignment. *BJU International*. 2008; 101 (2): 259; author reply, 259–260.
  25. Dorff TB, Shazer RL, Nepomuceno EM, Tucker SJ. Successful treatment of metastatic androgen-independent prostate carcinoma in a transsexual patient. *Clinical Genitourinary Cancer*. 2007; 5 (5): 344–346.
  26. Asscheman H, Giltay EJ, Megens JA, et al. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. *European Journal of Endocrinology*. 2011; 164 (4): 635–642.
  27. Wierckx K, Mueller S, Weyers S, et al. Long-term evaluation of cross-sex hormone treatment in transsexual persons. *Journal of Sexual Medicine*. 2012; 9 (10): 2641–2651.
  28. Turo R, Jallad S, Prescott S, Cross WR. Metastatic prostate cancer in transsexual diagnosed after three decades of estrogen therapy. *Canadian Urological Association Journal*. 2013; 7 (7–8): E544–546.
  29. Brown GR, Jones KT. Incidence of breast cancer in a cohort of 5,135 transgender veterans. *Breast Cancer Research and Treatment*. 2015; 149 (1): 191–198.
  30. Ellent E, Matrana MR. Metastatic prostate cancer 35 years after sex reassignment surgery. *Clinical Genitourinary Cancer*. 2016; 14 (2): e207–209.

31. Krakowsky Y, Ferrara S, Kulkarni G, Grober E. Active surveillance for low risk prostate cancer in a trans female—A case study and knowledge gap. *Journal of Sexual Medicine*. 14 (2): e92.
32. Thomas C, Wootten A, Robinson P. The experiences of gay and bisexual men diagnosed with prostate cancer: Results from an online focus group. *European Journal of Cancer Care*. 2013; 22 (4): 522–529.
33. Arrington MI. Sexuality, society, and senior citizens: An analysis of sex talk among prostate cancer support group members. *Sexuality & Culture*. 2000; 4 (4): 45–74.
34. Walker LM, Robinson JW. A description of heterosexual couples' sexual adjustment to androgen deprivation therapy for prostate cancer. *Psycho-Oncology*. 2011; 20 (8): 880–888.
35. Kukula KC, Jackowich RA, Wassersug RJ. Eroticization as a factor influencing erectile dysfunction treatment effectiveness. *International Journal of Impotence Research*. 2014; 26 (1): 1–6.
36. Goldstone SE. The ups and downs of gay sex after prostate cancer treatment. *Journal of Gay and Lesbian Psychotherapy*. 2005; 9 (1 & 2): 43–55.
37. Lee TK, Handy AB, Kwan W, et al. Impact of prostate cancer treatment on the sexual quality of life for men-who-have-sex-with-men. *Journal of Sexual Medicine*. 2015; 12 (12): 2378–2386.
38. Ussher JM, Perz J, Rose D, et al. Threat of sexual disqualification: The consequences of erectile dysfunction and other sexual changes for gay and bisexual men with prostate cancer. *Archives of Sexual Behavior*. 2017; 46 (7): 2043–2057.
39. Chen L, Staubli SE, Schneider MP, et al. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: A trade-off network meta-analysis. *European Urology*. 2015; 68 (4): 674–680.
40. Jarow JP, Nana-Sinkam P, Sabbagh M, Eskew A. Outcome analysis of goal directed therapy for impotence. *Journal of Urology*. 1996; 155 (5): 1609–1612.
41. Corona G, Rastrelli G, Burri A, et al. First-generation phosphodiesterase type 5 inhibitors dropout: A comprehensive review and meta-analysis. *Andrology*. 2016; 4 (6): 1002–1009.
42. Chung E, Van CT, Wilson I, Cartmill RA. Penile prosthesis implantation for the treatment for male erectile dysfunction: Clinical outcomes and lessons learnt after 955 procedures. *World Journal of Urology*. 2013; 31 (3): 591–595.
43. Lewis RW, Witherington R. External vacuum therapy for erectile dysfunction: Use and results. *World Journal of Urology*. 1997; 15 (1): 78–82.
44. Ussher JM, Perz J, Gilbert E, et al. Renegotiating sex and intimacy after cancer: Resisting the coital imperative. *Cancer Nursing*. 2013; 36 (6): 454–462.
45. Reece M, Rosenberger JG, Schick V, et al. Characteristics of vibrator use by gay and bisexually identified men in the United States. *Journal of Sexual Medicine*. 2010; 7 (10): 3467–3476.

46. Trost LW, Munarriz R, Wang R, et al. External mechanical devices and vascular surgery for erectile dysfunction. *Journal of Sexual Medicine*. 2016; 13 (11): 1579–1617.
47. Raina R, Pahlajani G, Agarwal A, et al. Long-term potency after early use of a vacuum erection device following radical prostatectomy. *BJU International*. 2010; 106 (11): 1719–1722.
48. Baniel J, Israilov S, Segenreich E, Livne PM. Comparative evaluation of treatments for erectile dysfunction in patients with prostate cancer after radical retropubic prostatectomy. *BJU International*. 2001; 88 (1): 58–62.
49. Matheson L, Watson EK, Nayoan J, et al. A qualitative metasynthesis exploring the impact of prostate cancer and its management on younger, unpartnered and gay men. *European Journal of Cancer Care*. 2017; doi: 10.1111/ecc.12676.
50. Wassersug RJ, Westle A, Dowsett GW. Men's sexual and relational adaptations to erectile dysfunction after prostate cancer treatment. *International Journal of Sexual Health*. 2016; 29 (1): 69–79.
51. Li H, Gao T, Wang R. The role of the sexual partner in managing erectile dysfunction. *Nature Reviews Urology*. 2016; 13 (3): 168–177.
52. Dorey G. Partners' perspective of erectile dysfunction: Literature review. *British Journal of Nursing*. 2001; 10 (3): 187–195.
53. Althof SE. When an erection alone is not enough: Biopsychosocial obstacles to lovemaking. *International Journal of Impotence Research*. 2002; 14 (Suppl. 1): S99–S104.
54. Movsas TZ, Yechieli R, Movsas B, Darwish-Yassine M. Partner's perspective on long-term sexual dysfunction after prostate cancer treatment. *American Journal of Clinical Oncology*. 2016; 39 (3): 276–279.
55. Tsang V, Skead C, Palmer-Hague J, Wassersug RJ. Impact of prostate cancer treatments on men's sense of manhood: Implications for understanding masculinity. In preparation.
56. Rose D, Ussher JM, Perz J. Let's talk about gay sex: Gay and bisexual men's sexual communication with healthcare professionals after prostate cancer. *European Journal of Cancer Care*. 2017; 26 (1).
57. Kelly D, Sakellariou D, Fry S, Vougioukalou S. Heteronormativity and prostate cancer: A discursive paper. *Journal of Clinical Nursing*. 2017; 27 (1–2): 461–467.
58. Blank TO. Gay men and prostate cancer: Invisible diversity. *Journal of Clinical Oncology*. 2005; 23 (12): 2593–2596.
59. Sharif A, Malhotra NR, Acosta AM, et al. The development of prostate adenocarcinoma in a transgender male to female patient: Could estrogen therapy have played a role? *Prostate*. 2017; 77 (8): 824–828.
60. Deebel NA, Morin JP, Autorino R, et al. Prostate cancer in transgender women: Incidence, etiopathogenesis, and management challenges. *Urology*. 2017; 110: 166–171.